169 related articles for article (PubMed ID: 38485975)
1. Topical netarsudil for the treatment of primary corneal endothelial degeneration in dogs.
Casanova MI; Park S; Mayes MA; Roszak K; Ferneding M; Echeverria N; Bowman MAW; Michalak SR; Ardon M; Wong S; Le SM; Daley N; Leonard BC; Good KL; Li JY; Thomasy SM
Sci Rep; 2024 Mar; 14(1):6238. PubMed ID: 38485975
[TBL] [Abstract][Full Text] [Related]
2. Topical Ripasudil for the Treatment of Primary Corneal Endothelial Degeneration in Dogs.
Michalak SR; Kim S; Park S; Casanova MI; Bowman MAW; Ferneding M; Leonard BC; Good KL; Li JY; Thomasy SM
Transl Vis Sci Technol; 2022 Sep; 11(9):2. PubMed ID: 36048012
[TBL] [Abstract][Full Text] [Related]
3. Randomized, Double-Masked, Pilot Study of Netarsudil 0.02% Ophthalmic Solution for Treatment of Corneal Edema in Fuchs Dystrophy.
Price MO; Price FW
Am J Ophthalmol; 2021 Jul; 227():100-105. PubMed ID: 33737034
[TBL] [Abstract][Full Text] [Related]
4. The Role of Rho Kinase Inhibitors in Corneal Diseases.
Futterknecht S; Chatzimichail E; Gugleta K; Panos GD; Gatzioufas Z
Drug Des Devel Ther; 2024; 18():97-108. PubMed ID: 38264539
[TBL] [Abstract][Full Text] [Related]
5. Pilot Study of Corneal Clearance With the Use of a Rho-Kinase Inhibitor After Descemetorhexis Without Endothelial Keratoplasty for Fuchs Endothelial Corneal Dystrophy.
Davies E; Jurkunas U; Pineda R
Cornea; 2021 Jul; 40(7):899-902. PubMed ID: 33758139
[TBL] [Abstract][Full Text] [Related]
6. Case Series: Novel Utilization of Rho-Kinase Inhibitor for the Treatment of Corneal Edema.
Davies E
Cornea; 2021 Jan; 40(1):116-120. PubMed ID: 33269892
[TBL] [Abstract][Full Text] [Related]
7. Transient Reticular Cystic Corneal Epithelial Edema With Topical Netarsudil: A Case Series and Review.
LoBue SA; Moustafa GA; Vu A; Amin M; Nguyen T; Goyal H
Cornea; 2021 Aug; 40(8):1048-1054. PubMed ID: 33369939
[TBL] [Abstract][Full Text] [Related]
8. Effects of 0.02% netarsudil ophthalmic solution on intraocular pressure of normotensive dogs.
Yang VY; Miller PE; Keys DA; La Croix NC
Vet Ophthalmol; 2021 Mar; 24 Suppl 1():87-95. PubMed ID: 31908139
[TBL] [Abstract][Full Text] [Related]
9. Effects of Netarsudil and Latanoprost Alone and in Fixed Combination on Corneal Endothelium and Corneal Thickness: Post-Hoc Analysis of MERCURY-2.
Wisely CE; Sheng H; Heah T; Kim T
Adv Ther; 2020 Mar; 37(3):1114-1123. PubMed ID: 31981106
[TBL] [Abstract][Full Text] [Related]
10. Effects of Netarsudil on the Corneal Endothelium: Three-Month Findings from a Phase 3 Trial.
Mundorf T; Mah F; Sheng H; Heah T
Ophthalmol Glaucoma; 2020; 3(6):421-425. PubMed ID: 33250082
[TBL] [Abstract][Full Text] [Related]
11. Rhopressa-induced corneal edema: a case report.
Chu MJ; Song M; Palmares T; Song A; Song J
J Med Case Rep; 2021 Apr; 15(1):182. PubMed ID: 33810801
[TBL] [Abstract][Full Text] [Related]
12. Randomized, Double-Masked Trial of Netarsudil 0.02% Ophthalmic Solution for Prevention of Corticosteroid-Induced Ocular Hypertension.
Price MO; Feng MT; Price FW
Am J Ophthalmol; 2021 Feb; 222():382-387. PubMed ID: 33045216
[TBL] [Abstract][Full Text] [Related]
13. Reticular epithelial corneal edema as a novel side-effect of Rho Kinase Inhibitors: An Indian scenario.
Bhargava M; Sen S; Bhambhani V; Paul RS; Dutta C
Indian J Ophthalmol; 2022 Apr; 70(4):1163-1170. PubMed ID: 35326007
[TBL] [Abstract][Full Text] [Related]
14. Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma.
Lin CW; Sherman B; Moore LA; Laethem CL; Lu DW; Pattabiraman PP; Rao PV; deLong MA; Kopczynski CC
J Ocul Pharmacol Ther; 2018; 34(1-2):40-51. PubMed ID: 28609185
[TBL] [Abstract][Full Text] [Related]
15. Phase 2, Randomized, Open-Label Parallel-Group Study of Two Dosing Regimens of Netarsudil for the Treatment of Corneal Edema Due to Fuchs Corneal Dystrophy.
Lindstrom RL; Lewis AE; Holland EJ; Sheppard JD; Hovanesian JA; Senchyna M; Hollander DA
J Ocul Pharmacol Ther; 2022 Dec; 38(10):657-663. PubMed ID: 36327101
[No Abstract] [Full Text] [Related]
16. Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2).
Kahook MY; Serle JB; Mah FS; Kim T; Raizman MB; Heah T; Ramirez-Davis N; Kopczynski CC; Usner DW; Novack GD;
Am J Ophthalmol; 2019 Apr; 200():130-137. PubMed ID: 30653957
[TBL] [Abstract][Full Text] [Related]
17. Canine endotheliitis: Clinical characteristics, advanced imaging features, and treatment.
Mayes MA; Casanova MI; Park S; Steele K; Linton L; Kim S; Good KL; Moore BA; Newbold GM; Leonard BC; Li JY; Thomasy SM
Vet Ophthalmol; 2022 May; 25 Suppl 1(Suppl 1):185-192. PubMed ID: 34971485
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of topically administered netarsudil (Rhopressa™) in normal and glaucomatous dogs with ADAMTS10-open-angle glaucoma (ADAMTS10-OAG).
Leary KA; Lin KT; Steibel JP; Harman CD; Komáromy AM
Vet Ophthalmol; 2021 Mar; 24 Suppl 1(Suppl 1):75-86. PubMed ID: 31872953
[TBL] [Abstract][Full Text] [Related]
19. Reversible Corneal Endothelial Abnormalities With Netarsudil.
Tanna AP; Esfandiari H; Teramoto K
J Glaucoma; 2020 Jun; 29(6):e41-e43. PubMed ID: 32224803
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of topically administered netarsudil-latanoprost fixed dose combination (FDC; Rocklatan™) in normal and glaucomatous dogs with ADAMTS10-open-angle glaucoma (ADAMTS10-OAG).
Leary KA; Steibel JP; Harman CD; Anderson AL; Komáromy AM
Vet Ophthalmol; 2021 Nov; 24(6):610-619. PubMed ID: 34085750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
